Bevacizumab safety in Japanese patients with colorectal cancer

Volume: 46, Issue: 3, Pages: 234 - 240
Published: Jan 15, 2016
Abstract
Bevacizumab (Avastin(®)) was approved in Japan in April 2007 for patients with advanced or metastatic colorectal cancer. To address the limited clinical experience in Japanese patients, a post-approval surveillance study was undertaken in bevacizumab-treated patients in Japan.Bevacizumab (5 or 10 mg/kg every 2 weeks) was administered with chemotherapy; patients were observed for 26 weeks from initiation of treatment. The primary objective was to...
Paper Details
Title
Bevacizumab safety in Japanese patients with colorectal cancer
Published Date
Jan 15, 2016
Volume
46
Issue
3
Pages
234 - 240
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.